论文部分内容阅读
[目的]探讨胃癌前病变与胃窦部P物质(SP)、血管活性肠肽(VIP)、降钙素基因相关肽(CGRP)的关系及健脾化瘀中药的治疗机制。[方法]采用N-甲基-N-硝基-N-亚硝基胍(MNNG)合并胃黏膜机械损伤方法制作胃癌前病变大鼠模型。选用健脾化瘀中药进行预防和治疗给药,观察了大鼠模型胃黏膜病理形态变化,同时用免疫组化法检测了SP、VIP、CGRP含量变化。[结果]胃窦部SP、CGRP的含量,中药组比西药组有明显提高(P<0.05),但VIP含量两组比较差异无显著性。(P>0.05)[结论]无论是预防还是治疗给药,健脾化瘀中药均能提高大鼠胃窦部SP、VIP、CGRP的含量。
[Objective] To investigate the relationship between gastric precancerous lesions and substance P (SP), vasoactive intestinal peptide (VIP) and calcitonin gene related peptide (CGRP) in gastric antrum and the therapeutic mechanism of Chinese medicine for spleen and removing blood stasis. [Method] The gastric precancerous lesion rat model was made by the method of N-methyl-N-nitro-N-nitrosoguanidine (MNNG) combined with mechanical injury of gastric mucosa. The Chinese medicine of invigorating the spleen and removing blood stasis was used for prophylaxis and treatment administration. The gastric mucosa pathological changes of the model rats were observed. At the same time, the contents of SP, VIP and CGRP were detected by immunohistochemistry. [Results] The contents of SP and CGRP in gastric antrum were significantly increased in traditional Chinese medicine group compared with western medicine group (P <0.05), but there was no significant difference in VIP content between the two groups. (P> 0.05) [Conclusion] The Chinese herbal medicine for invigorating the spleen and removing stasis can improve the content of SP, VIP and CGRP in the gastric antrum of rats.